AP

Aphaia Pharma at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

Aphaia Pharma takes part in 2 sessions at TIDES Europe 2026 in Amsterdam. Its sessions focus on obesity and metabolic treatment, including the European path from lab to launch. The most specific topic is a beaded oral glucose formulation that activates enteroendocrine cells for a multi-hormonal approach to metabolic regulation.

OrganizationTIDES Europe 2026 Attendance
AP
Aphaia Pharma
Biotech
Develops oral treatments for obesity and metabolic disease, including a beaded glucose formulation that activates enteroendocrine cells.
Talk
Fri Nov 6
09:10–10:00
Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape
What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for.
Post-event symposium · with Cantoni Therapeutics, Novo Nordisk, Constructive Bio
Talk
Fri Nov 6
14:15–14:30
Presentation: Enteroendocrine Cell Activation via Beaded Oral Glucose: A Multi-Hormonal Approach to Metabolic Regulation
Post-event symposium: Technology and Process Innovation Spotlight

Explore the full TIDES Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full TIDES Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Aphaia Pharma

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction